Expediting drug development--the FDA's new "breakthrough therapy" designation.

نویسندگان

Rachel E Sherman

Jun Li

Stephanie Shapley

Melissa Robb

Janet Woodcock

چکیده

The FDA's new "breakthrough therapy" designation for investigational drugs adds to the agency's portfolio of expedited programs for serious conditions. The designation requires preliminary clinical evidence demonstrating substantial improvement over existing therapies.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies

In the past few decades, with improved understanding of the genomic and immunologic underpinnings of cancer, better molecular characterization of tumors, and more precisely targeted agents, new and innovative therapeutics have altered the natural histories of certain cancer types such as chronic myeloid leukemia (CML), multiple myeloma, and melanoma. Recognizing a need to further expedite devel...

متن کامل

Accelerated approval and breakthrough therapy designation: oncology drug development on speed?

Recent advances in biotechnology have led to discoveries resulting in major improvements in the therapy of refractory malignancies, although most advanced cancers remain incurable. Thus, there is global consensus around the need to streamline the drug approval process for effective agents. Accelerated Approval and Breakthrough Therapy Designation hold the promise of making new treatments availa...

متن کامل

Developing standards for breakthrough therapy designation in oncology.

In July 2012, Congress passed the Food and Drug Administration Safety and Innovation Act (FDASIA). The Advancing Breakthrough Therapies for Patients Act was incorporated into a Title of FDASIA to expedite clinical development of new, potential "breakthrough" drugs or treatments that show dramatic responses in early-phase studies. Using this regulatory pathway, once a promising new drug candidat...

متن کامل

White Paper Examining Manufacturing Readiness for Breakthrough Drug Development

In July 2012, Congress passed the Advancing Breakthrough Therapies for Patients Act as part of the Food and Drug Administration Safety and Innovation Act (FDASIA). Section 902 of FDASIA provides for designation of a drug as a breakthrough therapy Bif the drug is intended alone or in combination with one or more other drugs, to treat serious or life-threatening diseases or conditions and prelimi...

متن کامل